JPRN-UMIN000000872已完成1 期
Predetermined Minor Histocompatibility Antigen-based Therapeutic or Prophylactic Peptide Vaccinations for Patients with Recurred Malignancies or Patients with High-Risk Malignancies Follwoing Allogeneic Hematopoietic Cell Transplantation. - Prevention or Treatment of Recurring Malignancies after Allongeneic Transplantation with Minor Antigen Peptides
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) CNS involvement or uncontrollable extramedullary disease. (2) Severe infections (including active tuberculosis) or double cancer. (3) Patients treated with major tranquilizer or antidepressant. (4) One of the following: positive HBs antigen, seropositive to HCV, seropositive to HIV, seropositive to HTLV-1, seropositive to STS. (5) Other reasons not eligible for vaccination (decision by physicians). (6) Past history of acute GVHD >= grade 3. (7) With more than grade 3 non-hematological toxicity at 10 days prior to vaccination. (8) Within 10 days after previous chemotherapy and neutrophil counts less than 200/mm^3. (9) On corticosteroid treatment. (10) Lack of availability for immunological and clinical follow-up assessments.
研究者
相似试验
进行中（未招募）
不适用
Donor Dendritische Cellen vaccinatie bij hematologische maligne aandoeningeEUCTR2012-002435-28-NLniversity Medical Center Utrecht
已完成
2 期
A phase I/II *minor histocompatibility antigen (mHag)-based Dendritic cell (DC) vaccination trial after allogeneic Stem Cell Transplantation (allo-SCT) to improve the safety and efficacy of donor lymphocyte infusions.bone marrow and lymphatic organscancers of the bloodhematological malignacy10035227NL-OMON37500niversitair Medisch Centrum Utrecht30
已完成
不适用
Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation (a phase I study)blood cell cancerhematological malignancies10027656NL-OMON40014niversitair Medisch Centrum Sint Radboud10
进行中（未招募）
1 期
Dendritic cells vaccination after allogeneic stem cell transplantatioPatients with aggressive hematological malignancies treated with allogeneic stem cell transplantationEUCTR2012-002879-34-NLRadboud University Nijmegen Medical Centre
撤回
2 期
A phase I/II *minor histocompatibility antigen UTA2-1 loaded, PD-L silenced Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of Donor Lymphocyte Infusions.hematological B cell malignancies blood cell cancer10027656NL-OMON43853Vrije Universiteit Medisch Centrum12